Two Postmarket NME Safety Reviews Done; Five To Be Finished By Early ’08
Executive Summary
FDA has completed safety reviews for two new molecular entities as part of a pilot program to determine whether preparing postmarket safety profiles would enhance the existing system for monitoring adverse events
You may also be interested in...
FDA's Post-Market NME Safety Reviews "Useful," But May Not Continue
Evaluations lead to labeling changes but were resource-intensive, according to agency's final report on a pilot program involving five NMEs.
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain